

Certificate of Analysis

Print Date: Aug 17th 2017

www.tocris.com

Product Name: B2 Catalog No.: 2855 Batch No.: 1

115687-05-3 CAS Number:

Batch Molecular Structure:

IUPAC Name: 5-[4-(4-Chlorobenzoyl)-1-piperazinyl]-8-nitroquinoline

1. PHYSICAL AND CHEMICAL PROPERTIES

Batch Molecular Formula: $C_{20}H_{17}CIN_4O_3.$ 4 H_2O

401.33 **Batch Molecular Weight:**

Physical Appearance: Yellow solid

Solubility: DMSO to 100 mM ethanol to 10 mM

Store at +4°C

Storage:

2. ANALYTICAL DATA

TLC: $R_f = 0.28$ (Ethyl acetate:Petroleum ether [1:1])

HPLC: Shows >98.1% purity ¹H NMR: Consistent with structure Mass Spectrum: Consistent with structure

Microanalysis: Carbon Hydrogen Nitrogen

> Theoretical 59.86 4.39 13.96 Found 60.12 13.57 4.45



Product Information

Print Date: Aug 17th 2017

www.tocris.com

Product Name: B2 Catalog No.: 2855 Batch No.: 1

CAS Number: 115687-05-3

IUPAC Name: 5-[4-(4-Chlorobenzoyl)-1-piperazinyl]-8-nitroquinoline

Description:

Promotes inclusion formation in cellular models of Huntington's disease and Parkinson's disease. Prevents mutant huntingtin-mediated proteasome dysfunction and reduces α -synuclein-mediated toxicity.

Physical and Chemical Properties:

Batch Molecular Formula: C₂₀H₁₇CIN₄O₃.1/4H₂O

Batch Molecular Weight: 401.33 Physical Appearance: Yellow solid

Minimum Purity: >98%

Batch Molecular Structure:

Storage: Store at +4°C

Solubility & Usage Info:

DMSO to 100 mM ethanol to 10 mM

Stability and Solubility Advice:

Some solutions can be difficult to obtain and can be encouraged by rapid stirring, sonication or gentle warming (in a 45-60°C water bath).

Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide. Our standard recommendations are:

SOLIDS: Provided storage is as stated on the product label and the vial is kept tightly sealed, the product can be stored for up to 6 months from date of receipt.

SOLUTIONS: We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials at -20°C or below and used within 1 month. Wherever possible solutions should be made up and used on the same day.

References:

Bodner et al (2006) Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parksinson's diseases. Proc.Natl.Acad.Sci.USA **103** 4246.

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use